GFAP and Alzheimer disease: Excitingly, in the 2023 AAIC, a new biomarker categorification was introduced for staging and AD prognosis: biomarkers of inflammatory/immune processes (I), currently only reflected by body fluid, e.g., plasma or cerebrospinal fluid (CSF) glial fibrillary acidic protein (GFAP) [5].